Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526338 · ClinicalTrials.gov registry record · Phase 2
Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone
A Phase 2 study of Hepatocellular Carcinoma, sponsored by Robert C. Martin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 1
- Study location
NCT06526338 is a Phase 2 study of Hepatocellular Carcinoma that is actively recruiting participants, run by Robert C. Martin. The registered enrollment target is 126 participants, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06526338, a Phase 2 study of Hepatocellular Carcinoma, is actively recruiting participants, sponsored by Robert C. Martin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of a single injection of IP-001 as adjuvant therapy after local ablation or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
Conditions Studied
Interventions
- DRUG 1.0% IP-001 for injection
- PROCEDURE Surgical Resection and Local Ablation
- PROCEDURE Local Ablation Alone
Study Locations (1)
Kentucky
- University of Louisville - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2024-07-24 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06526338
The ClinicalTrials.gov registry entry for NCT06526338 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (51% lower). The listed sponsor is Robert C. Martin, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which 1.0% IP-001 for injection is the first listed.
NCT06526338 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT06526338 about?
NCT06526338 is a clinical study titled "Adjuvant IP-001 Treatment for HCC Patients Following Surgical Resection and Ablation or Ablation Alone". The purpose of this study is to evaluate the safety and efficacy of a single injection of IP-001 as adjuvant therapy after local ablation or surgical resection and ablation in patients with hepatocellular carcinoma (HCC).
What is the current status of trial NCT06526338?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2024-07-24. Estimated completion is 2030-12.
What conditions does trial NCT06526338 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma.
What interventions are being tested in trial NCT06526338?
The interventions under investigation include: 1.0% IP-001 for injection (DRUG), Surgical Resection and Local Ablation (PROCEDURE), Local Ablation Alone (PROCEDURE).
Who is sponsoring clinical trial NCT06526338?
This trial is sponsored by Robert C. Martin, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06526338 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Combination of TATE and PD-1 Inhibitor in Liver Cancer
RECRUITING · Phase 2
-
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.